Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system. / Edvinsson, Jacob Carl Alexander; Jagd Grell, Anne-Sofie ; Warfvinge, Karin; Sheykhzade, Majid; Edvinsson, Lars; Haanes, Kristian Agmund.

In: Cephalalgia, Vol. 40, No. 12, 01.10.2020, p. 1296-1309 .

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Edvinsson, JCA, Jagd Grell, A-S, Warfvinge, K, Sheykhzade, M, Edvinsson, L & Haanes, KA 2020, 'Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system', Cephalalgia, vol. 40, no. 12, pp. 1296-1309 . https://doi.org/10.1177/0333102420929026

APA

Edvinsson, J. C. A., Jagd Grell, A-S., Warfvinge, K., Sheykhzade, M., Edvinsson, L., & Haanes, K. A. (2020). Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system. Cephalalgia, 40(12), 1296-1309 . https://doi.org/10.1177/0333102420929026

Vancouver

Edvinsson JCA, Jagd Grell A-S, Warfvinge K, Sheykhzade M, Edvinsson L, Haanes KA. Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system. Cephalalgia. 2020 Oct 1;40(12):1296-1309 . https://doi.org/10.1177/0333102420929026

Author

Edvinsson, Jacob Carl Alexander ; Jagd Grell, Anne-Sofie ; Warfvinge, Karin ; Sheykhzade, Majid ; Edvinsson, Lars ; Haanes, Kristian Agmund. / Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system. In: Cephalalgia. 2020 ; Vol. 40, No. 12. pp. 1296-1309 .

Bibtex

@article{dd93d8fa9ef7469db12a26754422972d,
title = "Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system",
abstract = "Background: Several neurotransmitters are expressed in the neurons of the trigeminal ganglion. One such signalling molecule is the pituitary adenylate cyclase-activating peptide (PACAP). PACAP signalling has been suggested to have a possible role in the pathophysiology of primary headaches. Objective: The present study was designed to investigate the relationship between PACAP and calcitonin gene-related peptide, currently the two most relevant migraine peptides. Methods: In the current study, we used ELISA to investigate PACAP and calcitonin gene-related peptide release in response to 60 mM K+ or capsaicin using a rat hemi-skull model. We combined this analysis with qPCR and immunohistochemistry to study the expression of PACAP and calcitonin gene-related peptide receptors and ligands. Results: Calcitonin gene-related peptide (CGRP) is released from the trigeminal ganglion and dura mater. In contrast, PACAP is only released from the trigeminal ganglion. We observed a weak correlation between the stimulated release of the two neuropeptides. PACAP-38 immunoreactivity was expressed alone and in a subpopulation of neurons in the trigeminal ganglion that also store calcitonin gene-related peptide. The receptor subtype PAC1 was mainly expressed in the satellite glial cells (SGCs), which envelop the neurons in the trigeminal ganglion, in some neuronal processes, inside the Ad-fibres and in the outermost layer of the myelin sheath that envelopes the Ad-fibres. Conclusion: Unlike CGRP, PACAP is only released within the trigeminal ganglion. This raises the question of whether a migraine therapy aimed at preventing peripheral PACAP signalling would be as successful as the CGRP signalling targeted treatments.",
author = "Edvinsson, {Jacob Carl Alexander} and {Jagd Grell}, Anne-Sofie and Karin Warfvinge and Majid Sheykhzade and Lars Edvinsson and Haanes, {Kristian Agmund}",
note = "Sensory nervous system, PACAP, CGRP, PAC1 receptor, hemi-skull model, trigeminal ganglion",
year = "2020",
month = oct,
day = "1",
doi = "10.1177/0333102420929026",
language = "English",
volume = "40",
pages = "1296--1309 ",
journal = "Cephalalgia",
issn = "0800-1952",
publisher = "SAGE Publications",
number = "12",

}

RIS

TY - JOUR

T1 - Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system

AU - Edvinsson, Jacob Carl Alexander

AU - Jagd Grell, Anne-Sofie

AU - Warfvinge, Karin

AU - Sheykhzade, Majid

AU - Edvinsson, Lars

AU - Haanes, Kristian Agmund

N1 - Sensory nervous system, PACAP, CGRP, PAC1 receptor, hemi-skull model, trigeminal ganglion

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Background: Several neurotransmitters are expressed in the neurons of the trigeminal ganglion. One such signalling molecule is the pituitary adenylate cyclase-activating peptide (PACAP). PACAP signalling has been suggested to have a possible role in the pathophysiology of primary headaches. Objective: The present study was designed to investigate the relationship between PACAP and calcitonin gene-related peptide, currently the two most relevant migraine peptides. Methods: In the current study, we used ELISA to investigate PACAP and calcitonin gene-related peptide release in response to 60 mM K+ or capsaicin using a rat hemi-skull model. We combined this analysis with qPCR and immunohistochemistry to study the expression of PACAP and calcitonin gene-related peptide receptors and ligands. Results: Calcitonin gene-related peptide (CGRP) is released from the trigeminal ganglion and dura mater. In contrast, PACAP is only released from the trigeminal ganglion. We observed a weak correlation between the stimulated release of the two neuropeptides. PACAP-38 immunoreactivity was expressed alone and in a subpopulation of neurons in the trigeminal ganglion that also store calcitonin gene-related peptide. The receptor subtype PAC1 was mainly expressed in the satellite glial cells (SGCs), which envelop the neurons in the trigeminal ganglion, in some neuronal processes, inside the Ad-fibres and in the outermost layer of the myelin sheath that envelopes the Ad-fibres. Conclusion: Unlike CGRP, PACAP is only released within the trigeminal ganglion. This raises the question of whether a migraine therapy aimed at preventing peripheral PACAP signalling would be as successful as the CGRP signalling targeted treatments.

AB - Background: Several neurotransmitters are expressed in the neurons of the trigeminal ganglion. One such signalling molecule is the pituitary adenylate cyclase-activating peptide (PACAP). PACAP signalling has been suggested to have a possible role in the pathophysiology of primary headaches. Objective: The present study was designed to investigate the relationship between PACAP and calcitonin gene-related peptide, currently the two most relevant migraine peptides. Methods: In the current study, we used ELISA to investigate PACAP and calcitonin gene-related peptide release in response to 60 mM K+ or capsaicin using a rat hemi-skull model. We combined this analysis with qPCR and immunohistochemistry to study the expression of PACAP and calcitonin gene-related peptide receptors and ligands. Results: Calcitonin gene-related peptide (CGRP) is released from the trigeminal ganglion and dura mater. In contrast, PACAP is only released from the trigeminal ganglion. We observed a weak correlation between the stimulated release of the two neuropeptides. PACAP-38 immunoreactivity was expressed alone and in a subpopulation of neurons in the trigeminal ganglion that also store calcitonin gene-related peptide. The receptor subtype PAC1 was mainly expressed in the satellite glial cells (SGCs), which envelop the neurons in the trigeminal ganglion, in some neuronal processes, inside the Ad-fibres and in the outermost layer of the myelin sheath that envelopes the Ad-fibres. Conclusion: Unlike CGRP, PACAP is only released within the trigeminal ganglion. This raises the question of whether a migraine therapy aimed at preventing peripheral PACAP signalling would be as successful as the CGRP signalling targeted treatments.

U2 - 10.1177/0333102420929026

DO - 10.1177/0333102420929026

M3 - Journal article

C2 - 32486909

VL - 40

SP - 1296

EP - 1309

JO - Cephalalgia

JF - Cephalalgia

SN - 0800-1952

IS - 12

ER -

ID: 242576606